NYSE: TMOThermo Fisher Scientific Inc Stock
$478.88+7.37 (1.56%)
Updated Apr 9, 2021
TMO Price
$478.88
Fair Value Price
N/A
Market Cap
$189.80B
52 Week Low
$309.18
52 Week High
$532.57
P/E
29.76x
P/B
5.5x
P/S
5.73x
PEG
2.08x
Dividend Yield
0.18%
Revenue
$32.22B
Earnings
$6.38B
Gross Margin
49.7%
Operating Margin
24.14%
Profit Margin
19.8%
Debt to Equity
1
Operating Cash Flow
$8B
Beta
0.86
Next Earnings
Apr 20, 2021
Ex-Dividend
Mar 15, 2021
Next Dividend
Apr 16, 2021
Zen Score
High
Medium
Low
54
Industry average
Reasons for this score
TMO ($478.88) is trading below its intrinsic value of $1,020.07, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
TMO is poor value based on its earnings relative to its share price (29.76x), compared to the US market average (18.56x)
Valuation
TMO is good value based on its earnings relative to its share price (29.76x), compared to the US Diagnostics & Research industry average (46.83x)
Valuation
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.76x
Industry
46.83x
Market
18.56x
TMO is poor value based on its earnings relative to its share price (29.76x), compared to the US market average (18.56x)
Valuation
TMO is good value based on its earnings relative to its share price (29.76x), compared to the US Diagnostics & Research industry average (46.83x)
Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.5x
Industry
5.92x
Market
-0.01x
TMO is good value based on its book value relative to its share price (5.5x), compared to the US market average (-0.01x)
Valuation
TMO is good value based on its book value relative to its share price (5.5x), compared to the US Diagnostics & Research industry average (5.92x)
Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is poor value relative to its rate of earnings growth, measured by PEG ratio (2.08x)
Valuation
TMO's financial health
Profit margin
Revenue
$10.6B
Net Income
$2.5B
Profit Margin
23.7%
TMO's Earnings (EBIT) of $7.78B can safely cover interest payments on company debt ($21.74B)
Financials
TMO's profit margin has increased (+5.3%) in the last year from (14.5%) to (19.8%)
Financials
Assets to liabilities
Assets
$69.1B
Liabilities
$34.5B
Debt to equity
0.63
TMO's short-term assets ($21.96B) exceed its short-term liabilities ($10.30B)
Financials
TMO's long-term liabilities ($24.24B) exceed its short-term assets ($21.96B)
Financials
TMO's debt has increased relative to shareholder equity (1), over the past 5 years ago (0.91)
Financials
TMO's debt to equity ratio (1) is considered high
Financials
Cash flow
Operating
$3.3B
Investing
-$626.0M
Financing
-$49.0M
TMO's operating cash flow ($8.29B) is sufficient to service the company's debt ($21.74B)
Financials
Thermo Fisher Scientific Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.